EGL-002 / Egle Therap - LARVOL DELTA

Enhanced anti-tumor efficacy through prolonged plasma membrane retention of a novel anti-CCR8/IL2 mutein fusion antibody (Businesswire) - "Egle scientists present evidence on EGL-002, a novel anti-CCR8/IL2 mutein fusion antibody engineered to enhance Treg depletion in solid tumors. Via the dual binding of CCR8 and CD25 EGL-002 showed prolonged retention on the surface of tumor-infiltrating Tregs, avoiding the rapid internalization that limited the efficacy of conventional CCR8 antibodies. This led to superior ADCC and ADCP potency, resulting in near complete tumor Treg depletion and potent anti-tumor activity in mouse models and ex vivo human tumors."

Preclinical • Oncology • Solid Tumor

Enhanced anti-tumor efficacy through prolonged plasma membrane retention of a novel anti-CCR8/IL2 mutein fusion antibody (AACR 2025) - "Preclinical data highlight EGL-002 as a highly effective tumor Treg-depleting agent with potent anti-tumor activity. Its unique design positions it as a best-in-class therapeutic candidate for solid tumors, either as a standalone treatment or in combination with ICIs."

Clinical • Oncology • Solid Tumor • CCR8 • IL2 • IL2RA